Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer
BOTHELL, Wash.--(BW HealthWire)--Aug. 21, 2001--Seattle Genetics, Inc. (Nasdaq:SGEN - news) announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate.
The trial will evaluate SGN-15 in combination with the chemotherapeutic drug Taxotere®.
``This is the fourth potential indication for SGN-15, complementing our existing trials in breast, colon and prostate cancers,'' stated H. Perry Fell, Ph.D., Chief Executive Officer at Seattle Genetics. ``The broad range of cancers targeted by SGN-15 could provide us with large market opportunities.''
The study opened at two sites in Portland, Ore., with additional sites to be added in the near future. The randomized trial comparing SGN-15 plus Taxotere versus Taxotere alone is expected to enroll up to 60 patients... |
